Showing results (21-30 of 27) with videos related to
Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
Journal of Medicinal Chemistry|April 16, 2004
Dopamine D4 ligands and models of receptor activation: 2-(4-pyridin-2-ylpiperazin-1-ylmethyl)-1H-benzimidazole and related heteroarylmethylarylpiperazines exhibit a substituent effect responsible for additional efficacy tuningAndrew O Stewart, Marlon D Cowart, Robert B Moreland, et al.The Journal of Pharmacology and Experimental Therapeutics|July 28, 2004
ABT-963 [2-(3,4-difluoro-phenyl)-4-(3-hydroxy-3-methyl-butoxy)-5-(4-methanesulfonyl-phenyl)-2H-pyridazin-3-one], a highly potent and selective disubstituted pyridazinone cyclooxgenase-2 inhibitorRichard R Harris, Lawrence Black, Sekhar Surapaneni, et al.ACS Chemical Biology|April 3, 2019
Small Molecule and Pooled CRISPR Screens Investigating IL17 Signaling Identify BRD2 as a Novel Contributor to Keratinocyte Inflammatory ResponsesPeter F Slivka, Chen-Lin Hsieh, Alex Lipovsky, et al.Journal of Medicinal Chemistry|August 18, 2006
1-aryl-3-(4-pyridine-2-ylpiperazin-1-yl)propan-1-one oximes as potent dopamine D4 receptor agonists for the treatment of erectile dysfunctionTeodozyj Kolasa, Mark A Matulenko, Ahmed A Hakeem, et al.Journal of Medicinal Chemistry|July 9, 2004
Discovery of 2-(4-pyridin-2-ylpiperazin-1-ylmethyl)-1H-benzimidazole (ABT-724), a dopaminergic agent with a novel mode of action for the potential treatment of erectile dysfunctionMarlon Cowart, Steven P Latshaw, Pramila Bhatia, et al.Journal of Medicinal Chemistry|December 8, 2006
Discovery of 3-methyl-N-(1-oxy-3',4',5',6'-tetrahydro-2'H-[2,4'-bipyridine]-1'-ylmethyl)benzamide (ABT-670), an orally bioavailable dopamine D4 agonist for the treatment of erectile dysfunctionMeena V Patel, Teodozyj Kolasa, Kathleen Mortell, et al.Journal of Medicinal Chemistry|November 3, 2018
Identification of Selective Dual ROCK1 and ROCK2 Inhibitors Using Structure-Based Drug DesignAdrian D Hobson, Russell A Judge, Ana L Aguirre, et al.Pageof 3